Astrotech Corporation (NASDAQ: ASTC) — Form 10-Q summary
Reporting period: The filing covers the quarter and nine months ended March 31, 2022, the third quarter of fiscal 2022. The request metadata says “2020 Q3,” which does not match the filing’s stated period.
Business context
Astrotech commercializes mass spectrometry technology through wholly owned subsidiaries: 1st Detect (security and explosives detection), AgLAB (hemp and cannabis processing), and BreathTech (breath analysis). The TRACER 1000 is ECAC-certified and selling to customers accepting that certification; U.S. TSA cargo detection testing remained underway. The company said it had deployments or orders at about 20 locations in 13 countries.
Financial results
Amounts below are in millions of dollars, except per-share data and percentages.
| Metric | Three months ended Mar. 31, 2022 | Prior year | Nine months ended Mar. 31, 2022 | Prior year |
|---|---|---|---|---|
| Revenue | $0.097 | $0.054 | $0.845 | $0.324 |
| Gross profit / margin | $0.051 / 53% | $0.008 / 15% | $0.183 / 22% | $0.037 / 11% |
| Operating expenses | $2.198 | $2.348 | $6.643 | $5.988 |
| Operating loss | $(2.147) | $(2.340) | $(6.460) | $(5.951) |
| Net loss | $(2.100) | $(2.403) | $(6.309) | $(6.136) |
| Net loss per share | $(0.04) | $(0.13) | $(0.13) | $(0.42) |
Cash flow and liquidity: For the nine months, operating cash use was $5.164 million, investing cash use $0.370 million, and financing cash use $2.056 million, resulting in a $7.590 million decrease in cash. Cash and equivalents were $28.346 million at March 31, 2022, with short-term investments of $26.580 million; working capital was approximately $54.5 million. Management said liquidity was sufficient for fiscal 2022 and the immediate future.
Debt and obligations: The company repaid $2.0 million of related-party debt during the period; $0.5 million remained payable to CEO and Chairman Thomas Pickens, with maturity extended to September 5, 2022. Lease liabilities totaled $0.593 million. No off-balance-sheet arrangements were reported.
Changes versus prior period
- Quarterly revenue rose $43,000; nine-month revenue increased $521,000, primarily from TRACER 1000 sales, including to an airport checkpoint customer. The initial checkpoint systems were delivered in fiscal Q2 2022.
- Gross margin improved year over year, which management attributed to higher production, volume discounts, and product enhancements.
- Nine-month SG&A increased $1.2 million, mainly from higher equity compensation, legal expenses associated with derivative litigation, and directors’ fees. Total operating expenses also reflect the prior-year $544,000 corporate lease disposal charge.
- Cash declined from $35.936 million at June 30, 2021. The company cited operating costs and repayment of related-party notes and accrued interest. Prior-year financing included $33.5 million of stock issuance proceeds.
- Available-for-sale investments had $792,000 of unrealized losses at March 31, 2022, reflected in accumulated other comprehensive loss.
Outlook, risks, and unusual items
- No specific revenue or earnings guidance was provided. Management is pursuing commercialization across security, agriculture, and breath-analysis applications and said it may consider strategic transactions or additional financing if needed.
- TSA cargo detection testing was still in progress and delayed by COVID-19. Semiconductor and electronics shortages and increased raw-material and shipping costs could affect production and results; management said it was seeking alternative supplies and expected to pass cost inflation to customers.
- Nasdaq had notified the company of noncompliance with the $1.00 minimum bid-price rule, with an initial cure period ending June 20, 2022. Following an independent director’s death in April 2022, the company also reported noncompliance with board and audit-committee composition requirements and said it intended to appoint an additional independent director.
- A stockholder class and derivative action concerning a charter amendment remained subject to anticipated settlement approval; the Delaware Court of Chancery had validated the amendment in October 2021. The filing does not quantify a potential settlement cost.
- The CFO resigned effective April 15, 2022, and Jaime Hinojosa was appointed CFO, Treasurer, and Secretary. The filing states the resignation was not related to a disagreement with the company.
- Deferred tax assets were fully offset by a valuation allowance; the reported effective tax rate was approximately zero. The filing identifies approximately $300,000 of uncertain tax positions.
Important facts for investors to verify
- Progress, timing, and commercial implications of final TSA cargo detection testing and any U.S. approval.
- Subsequent sales, repeat orders, and customer concentration: two customers accounted for all quarterly revenue; three accounted for all nine-month revenue.
- Nasdaq bid-price and board-composition compliance status, including any cure actions or potential delisting implications.
- Repayment or refinancing of the $500,000 related-party note due September 2022, and the company’s cash burn against available cash and investments.
- Costs and resolution of the stockholder litigation, and actual effects of supply-chain constraints and pricing actions on margins and deliveries.